farnesol and deoxycytidine

farnesol has been researched along with deoxycytidine in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (50.00)	29.6817
2010's	2 (50.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Elad, G; Gana-Weisz, M; Haklai, R; Halaschek-Wiener, J; Jansen, B; Kloog, Y	1
Egozi, Y; Elad-Sfadia, G; Haklai, R; Kloog, Y	1
Bustinza-Linares, E; Kurzrock, R; Tsimberidou, AM	1
Donehower, R; Goldsweig, H; Hidalgo, M; Jimeno, A; Laheru, D; Le, DT; Linden, S; McAllister, F; Rajeshkumar, NV; Rudek, MA; Shah, P; Song, D; Taylor, G; Zhao, M	1

Reviews

1 review(s) available for farnesol and deoxycytidine

Article	Year
Salirasib in the treatment of pancreatic cancer. Future oncology (London, England), 2010, Volume: 6, Issue:6 Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Membrane; Clinical Trials, Phase I as Topic; Deoxycytidine; Disease-Free Survival; Drug Screening Assays, Antitumor; Farnesol; Farnesyltranstransferase; Galectins; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Nude; Middle Aged; Neoplasm Proteins; Neoplasms; Pancreatic Neoplasms; Protein Binding; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Salicylates; Signal Transduction	2010

Article

Year

Salirasib in the treatment of pancreatic cancer.

Future oncology (London, England), 2010, Volume: 6, Issue:6

Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Membrane; Clinical Trials, Phase I as Topic; Deoxycytidine; Disease-Free Survival; Drug Screening Assays, Antitumor; Farnesol; Farnesyltranstransferase; Galectins; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Nude; Middle Aged; Neoplasm Proteins; Neoplasms; Pancreatic Neoplasms; Protein Binding; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Salicylates; Signal Transduction

2010

Trials

1 trial(s) available for farnesol and deoxycytidine

Article	Year
Integrated preclinical and clinical development of S-trans, trans-Farnesylthiosalicylic Acid (FTS, Salirasib) in pancreatic cancer. Investigational new drugs, 2012, Volume: 30, Issue:6 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Farnesol; Female; Gemcitabine; Humans; Male; Mice; Mice, Nude; Middle Aged; Mitogen-Activated Protein Kinases; Pancreatic Neoplasms; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins p21(ras); ras Proteins; Salicylates; Tumor Burden; Xenograft Model Antitumor Assays	2012

Article

Year

Integrated preclinical and clinical development of S-trans, trans-Farnesylthiosalicylic Acid (FTS, Salirasib) in pancreatic cancer.

Investigational new drugs, 2012, Volume: 30, Issue:6

Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Farnesol; Female; Gemcitabine; Humans; Male; Mice; Mice, Nude; Middle Aged; Mitogen-Activated Protein Kinases; Pancreatic Neoplasms; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins p21(ras); ras Proteins; Salicylates; Tumor Burden; Xenograft Model Antitumor Assays

2012

Other Studies

2 other study(ies) available for farnesol and deoxycytidine

Article	Year
The Ras inhibitor S-trans,trans-farnesylthiosalicylic acid chemosensitizes human tumor cells without causing resistance. Clinical cancer research : an official journal of the American Association for Cancer Research, 2002, Volume: 8, Issue:2 Topics: Actins; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Caveolin 1; Caveolins; Deoxycytidine; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drug Resistance, Neoplasm; Enzyme Inhibitors; Farnesol; Gemcitabine; Humans; MAP Kinase Signaling System; Mice; Mice, Nude; Mitogen-Activated Protein Kinases; Phalloidine; ras Proteins; Rats; Salicylates; Time Factors; Tumor Cells, Cultured; Up-Regulation	2002
Orally administered FTS (salirasib) inhibits human pancreatic tumor growth in nude mice. Cancer chemotherapy and pharmacology, 2008, Volume: 61, Issue:1 Topics: Administration, Oral; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Chromatography, Liquid; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; Farnesol; Gemcitabine; Injections, Intraperitoneal; Mice; Mice, Nude; Pancreatic Neoplasms; Random Allocation; ras Proteins; Salicylates; Solvents; Survival Rate; Tandem Mass Spectrometry	2008

Article

Year

The Ras inhibitor S-trans,trans-farnesylthiosalicylic acid chemosensitizes human tumor cells without causing resistance.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2002, Volume: 8, Issue:2

Topics: Actins; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Caveolin 1; Caveolins; Deoxycytidine; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drug Resistance, Neoplasm; Enzyme Inhibitors; Farnesol; Gemcitabine; Humans; MAP Kinase Signaling System; Mice; Mice, Nude; Mitogen-Activated Protein Kinases; Phalloidine; ras Proteins; Rats; Salicylates; Time Factors; Tumor Cells, Cultured; Up-Regulation

2002

Orally administered FTS (salirasib) inhibits human pancreatic tumor growth in nude mice.

Cancer chemotherapy and pharmacology, 2008, Volume: 61, Issue:1

Topics: Administration, Oral; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Chromatography, Liquid; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; Farnesol; Gemcitabine; Injections, Intraperitoneal; Mice; Mice, Nude; Pancreatic Neoplasms; Random Allocation; ras Proteins; Salicylates; Solvents; Survival Rate; Tandem Mass Spectrometry

2008